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Human Plasmodium infection produces a robust adaptive immune response. Time
courses for 104 children followed for 42 days after initiation of Plasmodium
falciparum chemotherapy were assayed for antibody levels to the five isotypes of
human immunoglobulins (Ig) and 4 subclasses of IgG for 32 P. falciparum antigens
encompassing all 4 parasite stages of human infection. IgD and IgE against these
antigens were undetectable at 1:100 serum concentration, but other Ig isotypes and IgG
subclasses were consistently observed against all antigens. Five quantitative parameters
were developed to directly compare Ig response among isotypes and antigens: Cmax,
maximum antibody level; 1C, difference between Cmax and the antibody level at Day 0;
tmax, time in days to reach Cmax; t1/2, Ig signal half-life in days; tneg, estimated number
of days until complete loss of Ig signal. Classical Ig patterns for a bloodborne pathogen
were seen with IgM showing early tmax and IgG production highest among Ig isotypes.
However, some unexpected trends were observed such as IgA showing a biphasic
pattern for many antigens. Variability among these dynamics of Ig acquisition and loss
was noted for different P. falciparum antigens and able to be compared both quantitatively
and statistically. This parametrization methodology allows direct comparison of Ig
isotypes produced against various Plasmodium antigens following malaria infection, and
the same methodology could be applied to other longitudinal serologic studies from
P. falciparum or different pathogens. Specifically for P. falciparum seroepidemiological
studies, reliable and quantitative estimates regarding the IgG dynamics in human
populations can better optimize modeling efforts for serological outputs.
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INTRODUCTION
The vertebrate hosts of malaria have been required to endure
malaria infection for tens of millions of years, and fossil evidence
for Plasmodium and their predecessors far precedes the rise of the
genusHomo (1, 2). The introduction of standardized antimalarial
medications and therapeutics has only occurred very recently in
human history (3), and intense evolutionary pressure has been
placed on the human genome to alter traits of red blood cells
as well as ensure a vigorous, yet measured, immune response
against the parasite is elicited (4). Numerous mechanisms have
been elucidated that combat Plasmodium infection within both
the innate and adaptive arms of the immune system (5–
9). Understanding these mechanism has been crucial in the
development of the next generation of malaria vaccines (and
adjuvants), and the potential for novel therapeutics (3, 10–12).
Outside of understanding antimalarial immune responses for
prophylactic or therapeutic purposes, these immune functions
also result in informative biomarkers for exposure estimates and
epidemiological investigations (13–15).
Antibody-mediated immune responses to malaria have
been studied extensively in mammalian models and humans,
and association between malaria infection and production
of antibodies has been investigated since the mid-twentieth
century (16–18). More recently, purified malaria antigens in
the form of peptides and recombinant proteins have been
characterized for their specific abilities to induce B cell responses
and antibody production in exposed populations (14, 19–
22). The pre-dominance of antigens in laboratory use today
are produced during blood stage Plasmodium infection and
would be expected to be at abundant levels in the host blood
during the merozoite multiplication cycles. Outside of these
erythrocyte-stage antigens, antigens eliciting antibody and other
adaptive responses have also been identified for the other human
Plasmodium falciparum infection stages: sporozoite (23, 24),
liver (hepatocyte) (25), and sexual (gametocyte) (26). Class-
switched populations of both effector andmemory B cells develop
after malaria exposure in humans, and more recently, memory
B cells activated by Plasmodium antigens have been further
subdivided into “classical” and “atypical” (27, 28). While classical
B cell populations would more likely be developed over time by
repeated exposures and have undergone affinity maturation (29),
atypical populations of these antibody-secreting cells have been
shown by multiple studies to be potentially shorter-lived, and it
has been proposed these should not be consideredmemory B cells
at all (30, 31).
Here we present data showing the dynamics of all classes
of human antibody responses to a panel of 32 P. falciparum
antigens in convalescent children who had been successfully
treated for P. falciparum infection. Selected antigens covered
all stages of P. falciparum infection in the human host, and
additional antigens representing non-falciparum Plasmodia
and other non-malaria pathogens were included to assess
cross-binding or non-specific antibody/antigen interaction.
Children were sampled weekly until 42 days after treatment,
with all five immunoglobulin isotypes and the four subclasses of
IgG assayed for in blood samples for specific antigen binding.
Parameterization and direct comparison of Ig levels may
allow a more systematic examination of antibody responses
post-infection for and provide valuable frameworks for vaccine
evaluation and seroepidemiological studies. Quantitatively
contrasting the defined parameters for a study population among
Ig isotypes and among antigens can assist in elucidating the true
differences in humoral responses to infection or vaccination.
MATERIALS AND METHODS
Study Design
We analyzed blood samples from children followed
longitudinally after successful antimalarial treatment. We
determined the presence of and quantified the concentration of
antibodies to a panel of 37 antigens separately for IgA, IgD, IgE,
IgG1, IgG2, IgG3, IgG4, and IgM.
Sample Collection
Samples from therapeutic efficacy trials from 2017 in three
sentinel sites in Angola (32) were analyzed. Participants were
children 6 months to 11 years of age with uncomplicated
P. falciparum single-species infection who were treated with
artemisinin-based combination therapy, with follow-up blood
draws at 2, 3, 7, 14, 21, 28, 35, and 42 days post-treatment
(Supplementary Figure 1). Based on parasite presence over
the course of follow-up, participants were classified as having
adequate clinical and parasitological response or recurrence of
parasitemia. Data from patients with recurrence of parasitemia
were censored to only include time points preceding recurrence
of parasitemia. Following parental or guardian written informed
consent for each participant before enrollment, blood samples
were collected on Whatman 903 filter paper, dried overnight,
and stored in individual plastic bags with desiccant. The dried
blood spots (DBS) were transported at ambient temperature to
Centers for Disease Control and Prevention (CDC) laboratories
in Atlanta and processed at CDC within 12 months post-
collection in the field. A malaria naive panel of blood specimens
was acquired from blood donors without history of travel to
malaria endemic regions.
Antigens in Multiplex Bead Assay Panel
and Covalent Binding to Beads
Antibody response to a panel of 37 antigens was measured
(Supplementary Table 1). These included 32 antigens from
all stages of the P. falciparum parasite in the human host:
sporozoite, hepatic (liver) stage, erythrocytic (blood) stage, and
gametocyte (sexual) stage. The panel also included P. vivax and
P. malariaeMSP1-19 antigens to represent other humanmalarias
for which this population of Angolan children had the possibility
of previous exposure. Additionally, the panel contained three
non-malaria control antigens, including a non-Plasmodium
apicomplexan [SAG2A antigen from Toxoplasma gondii (33)], a
disease without natural humoral immunity [tetanus toxoid from
Clostridium tetani (34), Massachusetts Biological Laboratories,
Boston, MA], and a generic laboratory purification protein
(glutathione-S-transferase, GST, from Schistosoma japonicum) as
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an internal assay control. Parameter estimates were generated for
these control antigens as well for comparative purposes.
Antigens were previously optimized for coupling
conditions and covalently bound to magnetic microbeads
(MagPlex, Luminex Corp., Austin, TX) by the EDC/Sulfo-
NHS intermediate reaction as described previously
(35). Reactive esters were formed on the carboxylated
beads in the presence of 5mM EDAC [1-Ethyl-3-(3′-
dimethylaminopropyl)carbodiimide](EMDMillipore) and 5mM
Sulfo-NHS [N-hydroxysulfosuccinimide] (ThermoScientific)
under rotation for 20min. Carboxyl to antigen amine
crosslinking took place in buffers and concentrations
which had previously been optimized for each antigen
(Supplementary Table 1) either at pH 5 (0.85% NaCl and
0.05M 4-morpholineethanesulfonic acid, MES) or at pH 7.2
(phosphate buffered saline, PBS) under rotation for 2 h. Non-
specific protein binding was blocked by BSA incubation (PBS
pH 7.2, +1% BSA) for 30min and beads were resuspended
in blocking buffer (PBS, 0.05% Tween20, 1% BSA) with the
addition of 0.02% NaN3 and protease inhibitors as described
previously (35).
Dried Blood Spot Processing and Antibody
Detection Immunoassay
A 6mm circular punch of the dried blood spot (DBS)
corresponding to approximately 10 µL whole blood (and 5
uL serum with the assumption of 50% hematocrit) was taken
from the center of each DBS for elution. DBS punches were
placed in elution buffer which consisted of PBS, 0.5% Polyvinyl
alcohol (Sigma), 0.8% Polyvinylpyrrolidine (Sigma), 0.1% casein
(ThermoFisher), 0.5% BSA (Millipore), 0.3% Tween-20, 0.05%
sodium azide, and 3 ug/mL E. coli extract to prevent non-specific
binding. This elution step diluted the samples to 1:20 whole
blood, which corresponded to a serum dilution of∼1:40. For the
immunoassay, samples were added to assay plates at a final serum
dilution of 1:100.
Separate immunoassays were performed for the same samples
to detect and quantify IgA, IgD, IgE, IgM, IgG1, IgG2, IgG3, and
IgG4 responses. For washing between incubation steps, plates
were affixed to a plate magnet (Luminex Corp.) and gently tapped
for 1–2min before evacuating liquid. A mixture of all antigen
conjugated beads was prepared in reagent diluent (PBS, 0.05%
Tween20, 0.5% BSA, 0.025% NaN3), pipetted to each well (∼625
beads per well per region) on assay plate (BioPlex Pro plates,
BioRad, Hercules, CA), and washed 2×. Beads were incubated
with 50µL samples in assay wells for 90min under gentle shaking
at room temperature protected from light. After 3 washes, beads
were incubated with 50 µL biotinylated detection antibodies
specific for each Ig class or subclass at a concentration of 1:500
for 45min (Southern Biotech, Birmingham, AL: IgA, 9130; IgM,
9020; IgD, 9030; IgE, 9250; IgG1, 9052; IgG2, 9060; IgG3, 9210;
IgG4, 9200). Following 3 washes, beads were incubated with
50 µL streptavidin-phycoerythrin (Invitrogen, Waltham, MA)
at a concentration of 1:200 for 30min. Following 3 washes,
beads were incubated with 50 µL reagent diluent for 30min to
remove any loosely bound antibodies. After one wash, beads were
resuspended in 100µL PBS, briefly shaken, and read immediately
on a MAGPIX R© machine (Luminex Corp.) by collecting the
median fluorescence intensity (MFI) for a target of 50 beads per
region. From blank wells on each plate, the background (bg) assay
signal was removed from each samples’ MFI value, to provide a
final assay signal of MFI-bg which was used for analysis.
Statistical Analysis
Antibody assay signal vs. patient time from initiation of study
enrollment (first day of receipt of antimalarials) was plotted by
antigen and antibody class/subclass. A LOESS non-parametric
curve was fit to model the expected dynamics of antibody
acquisition and decay. For each patient’s time course for each
antigen and antibody isotype/subclass, five parameters were
calculated: Cmax, the maximum antibody concentration (as
indicated by the assay fluorescence signal); 1C, the difference
between Cmax and the antibody concentration at Day 0, tmax, the
time to reach maximum concentration; t1/2, the post-peak half-
life assuming first-order decay kinetics; and tneg, the expected
number of days until the signal would be expected to be below
the level of detection of the assay (parameters illustrated in
Figure 1). To estimate a level of detection for these specific
assay conditions, for each antibody response against each antigen,
a panel of 96 serum specimens from persons without history
of travel to malaria endemic regions was assayed at 1:100
concentration under the same assay conditions as described
above. The lognormal mean plus 3 standard deviations for the
assay signals of this sample set was used at the MFI-bg threshold
to denote a true positive assay signal for each Ig and antigen.
The distributions of the five parameters were plotted
separately for each antibody class/subclass across all antigens.
The distributions of the parameters were compared using
the Kolmogorov-Smirnov-test, with IgG1 as the reference
distribution (as the Ig consistently exhibiting the highest assay
signals). Finally, the distribution of the parameters was compared
for different antigens, stratifying by antibody class/subclass. All
analysis was done in R version 3.6.0 (R Foundation for Statistical
Computing, Austria, Vienna).
Ethical Review
Study participants consented to collection of malaria data from
provided blood samples. Secondary analysis of anonymized
samples was approved by the office of the Associate Director
of Science in the Center for Global Health at the CDC (Project
ID: 0900f3eb8193aa9d).
RESULTS
Serological Panel and Enrolled Participants
A panel of 37 antigens expressed by P. falciparum and other
pathogens (Supplementary Table 1) was utilized for multiplex
antibody detection in blood samples. A total of 889 samples from
time courses for 104 patients were assayed for antibodies with
patient characteristics provided in Supplementary Table 2. The
median age of enrollment was 3 years (range: 0.5–11) andmedian
parasite density at enrollment (baseline; Day 0) was 22,065
parasites/µL blood (range: 3,916–200,000). Enrollment was the
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FIGURE 1 | Illustrative example of the five parameters created to characterize post-treatment antibody (Ab) dynamics to Plasmodium antigens for each individual. The
parameters represent: Cmax, maximum Ab signal; 1C, maximum change in Ab signal; tmax, time to maximum Ab signal; t1/2, half-life of Ab signal (in days) after
maximum signal has been reached; and tneg, modeled time until signal is reduced to below the level of detection of the assay.
day the child presented to the health facility with symptomatic
malaria. Approximately half of all patients were female (47%),
and all were microscopy negative for malaria parasites at 3 days
after initiation of malaria chemotherapy. Of the 104 patients
included in this study, 89 (85.6%) provided the complete nine
part follow-up blood sampling series for Days 0, 2, 3, 7, 14, 21,
28, 35, and 42 (Supplementary Figure 1).
Development of Parameters and Examples
by Specific Antigens
The five parameters created for the antibody comparisons in
this study are illustrated in Figure 1 and further described
in Methods. While no measurable IgD or IgE binding was
detected for antigens in the multiplex panel at the 1:100 serum
dilution, there were measurable antibody responses of the
IgA, IgM and all 4 IgG subclasses to all antigens. Figure 2
shows the post-treatment dynamics for antibodies for these
classes and subclasses for four illustrative antigens spanning
four biological compartments of P. falciparum: sporozoite CSP,
hepatic-stage LSA1, erythrocytic-stage GLURP-R0, and sexual-
stage Pfg27 (corresponding plots for all antigens are shown in
Supplementary Figure 2). Antibody levels for IgM and all 4
IgG subclasses typically rose in the first 2 weeks post-treatment,
before declining by mirroring first-order rate kinetics (evidenced
by a linear decay on a semi-log plot). In contrast to IgM
and IgG, IgA levels consistently showed a different pattern,
rising in the first 2 weeks, hitting a nadir at 3–4 weeks post-
treatment, before rising again. This unique pattern in IgA
dynamics was observed for responses to nearly all malarial
antigens (Supplementary Figure 2).
Dynamics of Antibodies to Control
Antigens
Antibodies to PvMSP1-19 and PmMSP1-19 also showed post-
treatment increases, potentially suggestive of Ig cross-binding
potential among the PfMSP1-19 antigen and other species’
isoforms. Notably, there were also consistent slight rises in
antibody responses to the SAG2A Toxoplasma gondii antigen
among different Ig classes. However, Ig responses to the tetanus
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FIGURE 2 | Post-treatment dynamics of antibodies stratifying by Ig isotype/subclass to: sporozoite- stage CSP, hepatic-stage LSA1, erythrocytic-stage GLURP-R0
and sexual-stage Pfg27. Points on each plot represent individual sample assay signals, and solid lines represents LOESS fitting to all assay signal data for the specific
antigen and Ig class/subclass. Plots for all Igs against all antigens shown in Supplementary Figure 2.
toxoid and the generic GST antigens were largely unchanged
among the 42-day longitudinal follow-up samplings.
Parameter Estimates by Ig Isotype
Comparison of the five parameters by Ig isotype/subclass
revealed important differences (Figure 3). Peak antibody
response (Cmax) was highly variable among isotype and subclass,
and statistically-significant differences was observed among the
mean of all antigen responses except in comparing IgG2 to IgG4
and in comparing IgG3 to IgG4 responses (Table 1). Cmax was
generally highest for IgG1 followed by IgM, IgA, and the three
other IgG sub-classes (in descending order: IgG3, IgG2, and
IgG4). Amongst the IgG subclasses, the IgG1 Cmax responses
dwarfed the other IgG sub-classes by 1-2 orders of magnitude,
and the low observed signals for IgG2, IgG3, and IgG4 responses
precluded determination of t1/2 and tneg for most time-courses
and antigens. The median increase in antibody response (1C)
was lowest for IgM, though there was a high level of variation
among the antigen panel for all isotypes. Some antigens’ IgG1
1C response registered the largest 1C estimates for the antigen
panel. Overall, the time for individuals to reach peak response for
IgG1 antibodies (tmax) was statistically longer (mean: 12.2 days)
compared to IgA (10.0 days) and IgM (10.4 days) (p < 0.00067;
Table 1). The modeled half-life (t1/2) for temporal decrease in
assay signal was longest for the IgG1 responses compared to
IgM and IgA, and this finding was reemphasized in the higher
estimated persistence of detectable antibody response (tneg) of
IgG1 vs. the IgM and IgA classes.
Parameter Estimates Among 37 Antigens
on Multiplex Panel
There was substantial variability in the five summary parameters
when comparing estimates for the different individual antigens.
Figure 4 shows the distribution of the five parameters for the
IgG1 response as measured against all 37 antigens in this
study (corresponding figures for the other isotypes/subclasses
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FIGURE 3 | Distribution of the five post-treatment clearance parameters by Ig isotype/subclass for antibodies to malaria antigens in Angolan children treated for
Plasmodium falciparum malaria. Violin plots display data for all P. falciparum antigens with the median estimate as a white point, black bars as the interquartile range
(IQR), and whiskers extending 1.5 × IQR. Plots occasionally do not exist for IgG2 and/or IgG4 as not enough children samples provided quantifiable assay signals for
these subclasses. Statistical comparison among isotypes shown in Supplementary Table 2. MFI-bg: median fluorescence intensity minus background assay signal.
are shown in Supplementary Figures 3–5). The maximum assay
signal (Cmax) showed large variation across different antigens,
spanning >4 orders of magnitude for IgG1. The highest median
IgG1 Cmax was to PfMSP1-19, followed by Etramp 5 ag1, and
PfAMA1, and these three antigens also provoked the strongest
IgA, IgM, and IgG3 responses. The maximum observed increase
in antibody response (1C) was highest for the P. falciparum
erythrocyte-stage antigens among all Ig classes and sub-classes.
For IgG1 and IgG3, time to maximum concentration (tmax)
was longest for HRP2, with median tmax of 21 days for both
subclasses. The tmax for IgG1 was shortest for GLURP-R2 which
peaked on overage only 3 days post-treatment, with nearly all
individual responses peaking before 7 days. Estimated Ig half-
lives against different antigens spanned 2 orders of magnitude
for IgG1 but remained within one order of magnitude for the
other Ig isotypes/subclasses. Excluding the control antigens, the
longest t1/2 was observed in antibodies against PfMSP1-19, with
a median of 38 days, and the shortest for antibodies to the
two GLURP antigens and Rh4.2 (10–12 days). Post-treatment
duration of antibody positivity (tneg) followed this similar pattern
for IgG1, with a median of 408 days of seropositivity for
PfMSP1-19, more than double the next-most persistent response
(153 days for PfAMA1). For all tneg estimates among different
isotypes/subclasses, antigens representing the different stages of
human P. falciparum infection did not show generalizable trends
by infection stage and are intermingled throughout. Selected
examples of the personal variation in Ig dynamics are given for
single persons’ Ig response to multiple antigens across the 42-day
follow-up (Supplementary Figure 6).
DISCUSSION
This study investigated the binding of all isotypes of human
antibodies (and 4 subclasses of IgG) to a panel of 32 P. falciparum
antigens in children treated for P. falciparum infection and
followed up for 42 days. As only children older than 6
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TABLE 1 | Differences in empirical distributions of decay parameters by
immunoglobulin class/subclass, Kolmogorov-Smirnov p-value with red cells
highlighting statistically significant differences (p-val < 0.00067,
Bonferroni corrected).
IgA IgM IgG1 IgG2 IgG3 IgG4
Test in difference between Cmax
IgA - 0.000 0.000 0.000 0.000 0.000
IgM - 0.000 0.000 0.000 0.000
IgG1 - 0.000 0.000 0.000
IgG2 - 0.000 0.000
IgG3 - 0.000
IgG4 -
Test in difference between 1C
IgA - 0.000 0.000 0.004 0.012 0.000
IgM - 0.006 0.000 0.000 0.000
IgG1 - 0.000 0.000 0.000
IgG2 - 0.164 0.009
IgG3 - 0.000
IgG4 -
Test in difference between tmax
IgA - 0.000 0.000 0.000 0.000 0.000
IgM - 0.000 0.000 0.000 0.000
IgG1 - 0.000 0.000 0.000
IgG2 - 0.000 0.188
IgG3 - 0.204
IgG4 -
Test in difference between t1/2
IgA - 0.004 0.000 0.072 0.085 0.000
IgM - 0.000 0.517 0.282 0.000
IgG1 - 0.779 0.000 0.015
IgG2 - 0.151 0.023
IgG3 - 0.000
IgG4 -
Test in difference between tneg
IgA - 0.000 0.000 - 0.000 -
IgM - 0.000 - 0.000 -
IgG1 - - 0.037 -
IgG2 - - -
IgG3 - -
IgG4 -
months were enrolled in this study (32), and evidence has
been shown that any maternal-derived antibodies have waned
by this point in life (36, 37), the antibody data presented here
would be reasonably assumed to come from natural malaria
exposure and host adaptive immune responses. These results
reveal stark heterogeneities in antibody dynamics across different
antigens, among Ig isotype/subclass, and among individual
persons. At a 1:100 serum dilution, no measurable IgD or
IgE binding was detected for any of the P. falciparum or
control antigens, but IgA, IgM and all 4 IgG subclasses
were ubiquitously detected with the exception of IgG2 and
IgG4. Five response parameters were created and estimated
by this study to allow systematic comparison of magnitude of
response as well as the shape of the acquisition and decay
curve among antigens, antibody isotypes, and persons. Among
antibody classes, and even within the same class (i.e., IgG1),
there was substantial variability across the 32 P. falciparum
antigens [as suggested in some studies in other populations
(38, 39)] with all key parameters describing the shape of
the antibody dynamics varying by antigen, often over several
orders of magnitude. These data reinforce many of the classical
assumptions regarding the anti-pathogen humoral response to
bloodborne pathogens in terms of both Ig class dynamics
and interpersonal variability. Interestingly, IgM decay was not
markedly more rapid than IgG, similar to a recent report in
other populations (40). Furthermore, for the set of antigens in
this panel, the estimated half-life (t1/2) for IgG3 was not shorter
than IgG1, despite having an intrinsically quicker clearance
from blood.
This heterogeneity in the five parameters could potentially
be beneficial to the study of natural (or induced) immunity
to malaria, as it opens the possibility of picking and choosing
different Ig classes and antigens to design assays aimed at
characterizing previous malaria exposure. Our results suggest
antibodies to PfMSP1-19, a known marker for immunity against
P. falciparum (41), may be a putative “long-term” marker of
exposure to P. falciparum with IgG antibodies predicted to last
for years after infection (42). Individuals had robust responses
to PfMSP1-19 and the aggregated estimate of the IgG1 half-life
was 38 days, suggesting that individuals with exposure would
retain seropositivity several 100 days after the infection. Similarly,
PfAMA1 elicited a similarly strong IgG1 response with a long
half-life estimates (range: 23–30 days). Other antigens such as
Rh2_2020 and Etramp 5 ag 1 showed nearly as strong responses,
but the half-life of these responses was substantially shorter, on
the order of 16–21 days. On the other end of the spectrum,
responses to the GLURP antigens were also substantial, but
with rapid decay. An estimated half-life of around 10 days
suggests that the presence of a strong GLURP response is
evidence of active or very recent infection (43). Some vaccine
candidates showed good antibody induction by infection (e.g.,
PfAMA1, Rh2, PfMSP1, GLURP), whereas others had a weaker
response (e.g., RH5, CSP), which has been reported in other
populations (39). Other groups have also presented estimates
for antibody half-life as well as time to seronegativity in other
populations. A previous 3-year longitudinal study of naturally-
exposed Kenyan children estimated total IgG against PfAMA1
and PfMSP2 antigens would have a half-life of approximately
1 year or longer, and the majority of children were found
to retain seropositivity to these two antigens 1 year after
no detectable P. falciparum infections (44). However, even
only measuring IgG against this smaller panel of antigens,
high interpersonal variation was still observed in these study
populations (45). This study expands the analytical capacity of
predictive Ig response for vaccine or seroepidemiological studies
by introducing standardized parameters in which to compare
among a broad panel of 32 P. falciparum antigens among all
human Ig isotypes.
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FIGURE 4 | Distribution of acquisition and decay parameters for IgG1 to different antigens in Angolan children treated for malaria. Antigens are color-coded by
category: sporozoite (white), hepatic (pink), erythrocytic (blue), gametocyte (green), non-falciparum Plasmodium (violet) and other control (yellow). Boxplots display
median as black solid line with box length representing interquartile range (IQR) and whiskers 1.5 × IQR. Outliers above or below 1.5 × IQR represented as circles.
MFI-bg: median fluorescence intensity-background. Plots for parameter estimates for IgM, IgA, and IgG3 shown in Supplementary Figures 3–5, respectively.
The results revealed several unreported patterns in the
antibody dynamics following clearance of P. falciparum infection.
First, IgA responses against many antigens appear to be biphasic,
with a secondary increase in IgA response 3–4 weeks post-
treatment—thus not fitting well to a monotonic first-order decay
assumption. Second, we observed evidence of non-specific Ig
signals, with increases in non-P. falciparum malaria and non-
Plasmodium spp. responses for all Ig isotypes/subclasses. Some
limited cross-reactivity between responses to the Plasmodium
spp. MSP1-19 antigens has been shown before (35, 46), so
the increase in Plasmodium spp. MSP1 responses is likely
a combination of non-specific immune activation and cross-
binding among homologs.
The estimates for the parameters presented here are not
absolute, as the specific assay conditions used in this study
could confound the results, precluding definitive conclusions
regarding the expected antibody clearance dynamics. For the
assay, blood dried on filter paper was the only sample type
utilized, and potential exists for reduction of binding potential
of Ig after blood desiccation, though this sample type has
been shown to be robust in previous studies (35, 46, 47).
Additionally, the highest concentration of serum used in this
assay was 1:100, which may explain why anti-malarial IgE
was not detected in this current study whereas it has been
observed in low quantities in previous malaria serostudies (48,
49), and that IgG2 and IgG4 were frequently undetectable in
these samples. The multiplex assay beads used in the study
were coupled at antigen concentrations optimized by our group
for each antigen, so direct comparison of one antigen’s assay
signal to another is not necessarily an absolute indication of the
concentration of those antibodies in a blood sample. Regarding
the host side, neither the number of previous malaria episodes
nor the duration of the current infection was known for the
participants, and thus the antibody dynamics described here
are potentially a conflation of responses in both naive and
non-naive individuals with various degrees of immunological
memory, different durations of P. falciparum infection, and
different antibody affinities. Given this heterogeneity in host
factors, it is therefore even more remarkable that clear patterns
emerge from the data. The maximum duration of follow-up
was only 42 days, and thus the antibody dynamics beyond this
time point could not be characterized with specimen data and
needed to be predictively modeled. Specifically, what happens
to IgA responses for all antigens and the IgG responses to
HRP2, both of which showed tendencies to increase prior to
day 42, remain unanswered. Other groups have followed malaria
convalescent individuals or persons immunized with malaria
antigens for longer periods of time (14, 19, 50), and generation
of these five parameter estimates from those datasets of longer
study periods could provide a comparison to estimates obtained
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here. A similarity among all enrolled participants in this study
was the relative young age of this study population with the
median age of 3 years and the oldest participant at 11 years
old. The findings presented here should be interpreted in light
of this study population, as the humoral immune responses
in this young population may not be representative of other
study populations with a broader range of ages and living under
different transmission pressures.
Similar analyses on samples from patients followed during
other longitudinal studies in additional settings and of other
ages, and/or samples from controlled human infections, could
serve as a comparator dataset to determine if consistency would
exist in these parameter estimates for the same antigens among
different studies and populations. The present study highlights
the advantage of high-throughput antibody detection using the
multiplex bead-based assay and the amount of antibody data
that could be collected for an individual specimen. Overall, being
able to have predictive capacity around the humoral response
of a populace to P. falciparum infection can provide the best
information and assumptions needed for seroepidemiological
modeling and outputs to estimate falciparum malaria in a
population. In utilizing a multiplex assay format, multiple
targets, and multivariate analyses, an antibody profile could
be created for an individual which precisely estimates (with
confidence intervals) the time since last P. falciparum exposure,
and this information at community and population levels
would be valuable for estimation of historical transmission
in an area. With being able to create parameters for both
the acquisition of, as well as loss, of Ig signal following
P. falciparum infection, this work moves toward a scenario where
investigators can infer the timing of the last P. falciparum
exposure with increased accuracy and precision based on
serology alone.
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